Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18255094
Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44, 527-38 18255094
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y871-p - EGFR (mouse)
Modsite: LGAEEkEyHAEGGkV SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y869‑p, EGFR iso2 (human): , EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (rat) genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
Downstream Regulation
Effect of modification (process):  transcription, induced
Comments:  PAI-1 expression

T203-p - ERK1 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) inhibit treatment-induced increase homozygous null

Y205-p - ERK1 (mouse)
Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) inhibit treatment-induced increase homozygous null

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) inhibit treatment-induced increase homozygous null

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) inhibit treatment-induced increase homozygous null

S465-p - SMAD2 (mouse)
Modsite: sPSVRCSsMs_____ SwissProt Entrez-Gene
Orthologous residues
SMAD2 (human): S465‑p, SMAD2 (mouse): S465‑p, SMAD2 (rat): S465‑p, SMAD2 (cow): S465‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) augment treatment-induced increase homozygous null

S467-p - SMAD2 (mouse)
Modsite: SVRCSsMs_______ SwissProt Entrez-Gene
Orthologous residues
SMAD2 (human): S467‑p, SMAD2 (mouse): S467‑p, SMAD2 (rat): S467‑p, SMAD2 (cow): S467‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
TGF-beta EGFR (mouse) augment treatment-induced increase homozygous null

Y418-p - Src (mouse)
Modsite: RLIEDNEyTARQGAK SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y418‑p, Src iso1 (mouse): Y424‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase

Y870-p - EGFR (rat)
Modsite: LGAEEKEyHAEGGKV SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y869‑p, EGFR iso2 (human): , EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (rat) genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
SU6656 TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta no effect upon treatment-induced increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta inhibit treatment-induced increase
U0126 TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta inhibit treatment-induced increase
U0126 TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta inhibit treatment-induced increase
U0126 TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta inhibit treatment-induced increase
U0126 TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

S465-p - SMAD2 (rat)
Modsite: SPSVRCSsMs_____ SwissProt Entrez-Gene
Orthologous residues
SMAD2 (human): S465‑p, SMAD2 (mouse): S465‑p, SMAD2 (rat): S465‑p, SMAD2 (cow): S465‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta no effect upon treatment-induced increase
U0126 TGF-beta no effect upon treatment-induced increase
botulinum_C3_toxin TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

S467-p - SMAD2 (rat)
Modsite: SVRCSsMs_______ SwissProt Entrez-Gene
Orthologous residues
SMAD2 (human): S467‑p, SMAD2 (mouse): S467‑p, SMAD2 (rat): S467‑p, SMAD2 (cow): S467‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
AG1478 TGF-beta no effect upon treatment-induced increase
U0126 TGF-beta no effect upon treatment-induced increase
botulinum_C3_toxin TGF-beta inhibit treatment-induced increase
Y27632 TGF-beta inhibit treatment-induced increase

S423-p - SMAD3 (rat)
Modsite: SPSIRCSsVs_____ SwissProt Entrez-Gene
Orthologous residues
SMAD3 (human): S423‑p, SMAD3 (mouse): S423‑p, SMAD3 (rat): S423‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
Y27632 TGF-beta inhibit treatment-induced increase

S425-p - SMAD3 (rat)
Modsite: SIRCSsVs_______ SwissProt Entrez-Gene
Orthologous residues
SMAD3 (human): S425‑p, SMAD3 (mouse): S425‑p, SMAD3 (rat): S425‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
Y27632 TGF-beta inhibit treatment-induced increase

Y419-p - Src (rat)
Modsite: RLIEDNEyTARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y418‑p, Src iso1 (mouse): Y424‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), R22 ('muscle, smooth'), SYF (fibroblast), vascular smooth muscle cell ('muscle, smooth')
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
SU6656 TGF-beta inhibit treatment-induced increase
SU6656 decrease